{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T07:02:44Z","timestamp":1793689364692,"version":"4.5.1"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T00:00:00Z","timestamp":1778112000000},"content-version":"vor","delay-in-days":37,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-026-08063-8","type":"journal-article","created":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T16:56:47Z","timestamp":1774976207000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Monitoring of dual-drug combination therapy in pediatric epilepsy patients: a machine learning model for simultaneous VPA-LEV concentration-dose prediction"],"prefix":"10.1186","volume":"24","author":[{"given":"Yue-Wen","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Si","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Wei","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"He","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-Wen","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3491-8859","authenticated-orcid":false,"given":"Zhou-Jie","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,31]]},"reference":[{"key":"8063_CR1","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/nrneurol.2014.58","volume":"10","author":"JM Wilmshurst","year":"2014","unstructured":"Wilmshurst JM, Berg AT, Lagae L, Newton CR, Cross JH. The challenges and innovations for therapy in children with epilepsy. Nat Rev Neurol England. 2014;10:249\u201360. https:\/\/doi.org\/10.1038\/nrneurol.2014.58.","journal-title":"Nat Rev Neurol England"},{"key":"8063_CR2","doi-asserted-by":"publisher","first-page":"409","DOI":"10.3389\/fneur.2020.00409","volume":"11","author":"H Kim","year":"2020","unstructured":"Kim H, Yoo S, Jeon Y, Yi S, Kim S, Choi SA, et al. Characterization of Anti-seizure medication treatment pathways in pediatric epilepsy using the electronic health record-based common data model. Front Neurol Switzerland. 2020;11:409. https:\/\/doi.org\/10.3389\/fneur.2020.00409.","journal-title":"Front Neurol Switzerland"},{"key":"8063_CR3","doi-asserted-by":"publisher","first-page":"669","DOI":"10.2165\/00023210-200216100-00003","volume":"16","author":"W L\u00f6scher","year":"2002","unstructured":"L\u00f6scher W. Basic pharmacology of valproate: a review after 35 years of clinical use for the treatment of epilepsy. CNS Drugs New Zealand. 2002;16:669\u201394. https:\/\/doi.org\/10.2165\/00023210-200216100-00003.","journal-title":"CNS Drugs New Zealand"},{"key":"8063_CR4","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1016\/j.neuropharm.2007.11.021","volume":"54","author":"RM Kaminski","year":"2008","unstructured":"Kaminski RM, Matagne A, Leclercq K, Gillard M, Michel P, Kenda B, et al. SV2A protein is a broad-spectrum anticonvulsant target: functional correlation between protein binding and seizure protection in models of both partial and generalized epilepsy. Neuropharmacol. Engl. 2008;54:715\u201320. https:\/\/doi.org\/10.1016\/j.neuropharm.2007.11.021.","journal-title":"Neuropharmacol. Engl"},{"key":"8063_CR5","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.phrs.2016.02.014","volume":"106","author":"E Spina","year":"2016","unstructured":"Spina E, Pisani F, de Leon J. Clinically significant pharmacokinetic drug interactions of antiepileptic drugs with new antidepressants and new antipsychotics. Pharmacol Res Netherlands. 2016;106:72\u201386. https:\/\/doi.org\/10.1016\/j.phrs.2016.02.014.","journal-title":"Pharmacol Res Netherlands"},{"key":"8063_CR6","doi-asserted-by":"publisher","first-page":"2709","DOI":"10.3390\/ph3082709","volume":"3","author":"J Saruwatari","year":"2010","unstructured":"Saruwatari J, Ishitsu T, Nakagawa K. Update on the genetic polymorphisms of drug-metabolizing enzymes in antiepileptic drug therapy. Pharmaceuticals (Basel) Switzerland. 2010;3:2709\u201332. https:\/\/doi.org\/10.3390\/ph3082709.","journal-title":"Pharmaceuticals (Basel) Switzerland"},{"key":"8063_CR7","doi-asserted-by":"publisher","first-page":"100680","DOI":"10.1016\/j.bj.2023.100680","volume":"47","author":"S-N Lim","year":"2024","unstructured":"Lim S-N, Wu T, Chang C-W, Johnny Tseng W-E, Cheng M-Y, Hsieh H-Y, et al. Clinical impact of therapeutic drug monitoring for newer anti-seizure medications in patients with epilepsy: a real-world observation study. Biomed J United States. 2024;47:100680. https:\/\/doi.org\/10.1016\/j.bj.2023.100680.","journal-title":"Biomed J United States"},{"key":"8063_CR8","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.2165\/00003088-200645110-00002","volume":"45","author":"SI Johannessen","year":"2006","unstructured":"Johannessen SI, Tomson T. Pharmacokinetic variability of newer antiepileptic drugs: when is monitoring needed? Clin Pharmacokinet Switzerland. 2006;45:1061\u201375. https:\/\/doi.org\/10.2165\/00003088-200645110-00002.","journal-title":"Clin Pharmacokinet Switzerland"},{"key":"8063_CR9","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.2174\/1570159X19666210826125341","volume":"19","author":"E Aky\u00fcz","year":"2021","unstructured":"Aky\u00fcz E, K\u00f6kl\u00fc B, Ozenen C, Arulsamy A, Shaikh MF. Elucidating the potential side effects of current Anti-seizure drugs for epilepsy. Curr Neuropharmacol United Arab Emirates. 2021;19:1865\u201383. https:\/\/doi.org\/10.2174\/1570159X19666210826125341.","journal-title":"Curr Neuropharmacol United Arab Emirates"},{"key":"8063_CR10","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1007\/s40263-022-00955-9","volume":"36","author":"A Strzelczyk","year":"2022","unstructured":"Strzelczyk A, Schubert-Bast S. Psychobehavioural and cognitive adverse events of Anti-seizure medications for the treatment of developmental and epileptic encephalopathies. CNS Drugs New Zealand. 2022;36:1079\u2013111. https:\/\/doi.org\/10.1007\/s40263-022-00955-9.","journal-title":"CNS Drugs New Zealand"},{"key":"8063_CR11","doi-asserted-by":"publisher","unstructured":"Tan J, Paquette V, Levine M, Ensom MHH. Levetiracetam clinical pharmacokinetic monitoring in pediatric patients with epilepsy. Clin Pharmacokinet Switzerland. 2017;56:1267\u201385. https:\/\/doi.org\/10.1007\/s40262-017-0537-1.","DOI":"10.1007\/s40262-017-0537-1"},{"key":"8063_CR12","doi-asserted-by":"publisher","unstructured":"Chhun S, Jullien V, Rey E, Dulac O, Chiron C, Pons G. Population pharmacokinetics of levetiracetam and dosing recommendation in children with epilepsy. Epilepsia United States. 2009;50:1150\u201357. https:\/\/doi.org\/10.1111\/j.1528-1167.2008.01974.x.","DOI":"10.1111\/j.1528-1167.2008.01974.x"},{"key":"8063_CR13","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1111\/j.1528-1167.2007.01090.x","volume":"48","author":"TA Glauser","year":"2007","unstructured":"Glauser TA, Mitchell WG, Weinstock A, Bebin M, Chen D, Coupez R, et al. Pharmacokinetics of levetiracetam in infants and young children with epilepsy. Epilepsia United States. 2007;48:1117\u201322. https:\/\/doi.org\/10.1111\/j.1528-1167.2007.01090.x.","journal-title":"Epilepsia United States"},{"key":"8063_CR14","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.seizure.2023.05.010","volume":"109","author":"M Shi","year":"2023","unstructured":"Shi M, Liu C, He L, Wu H, Wu Y. Therapeutic drug monitoring and the therapeutic reference range of levetiracetam for Chinese patients: problems and issues. Seizure. Engl. 2023;109:26\u201333. https:\/\/doi.org\/10.1016\/j.seizure.2023.05.010.","journal-title":"Seizure. Engl"},{"key":"8063_CR15","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1016\/j.tibtech.2020.03.001","volume":"38","author":"HC Ates","year":"2020","unstructured":"Ates HC, Roberts JA, Lipman J, Cass AEG, Urban GA, Dincer C. On-site therapeutic drug monitoring. Trends Biotechnol England. 2020;38:1262\u201377. https:\/\/doi.org\/10.1016\/j.tibtech.2020.03.001.","journal-title":"Trends Biotechnol England"},{"key":"8063_CR16","doi-asserted-by":"publisher","first-page":"1228641","DOI":"10.3389\/fphar.2023.1228641","volume":"14","author":"L Zhang","year":"2023","unstructured":"Zhang L, Liu M, Qin W, Shi D, Mao J, Li Z. Modeling the protein binding non-linearity in population pharmacokinetic model of valproic acid in children with epilepsy: a systematic evaluation study. Front Pharmacol Switzerland. 2023;14:1228641. https:\/\/doi.org\/10.3389\/fphar.2023.1228641.","journal-title":"Front Pharmacol Switzerland"},{"key":"8063_CR17","doi-asserted-by":"publisher","first-page":"115716","DOI":"10.1016\/j.addr.2025.115716","volume":"227","author":"AM Talkington","year":"2025","unstructured":"Talkington AM, Cao Y, Kearsley AJ, Lai SK. Opportunities for machine learning and artificial intelligence in physiologically-based pharmacokinetic (PBPK) modeling. Adv Drug Deliv Rev Netherlands. 2025;227:115716. https:\/\/doi.org\/10.1016\/j.addr.2025.115716.","journal-title":"Adv Drug Deliv Rev Netherlands"},{"key":"8063_CR18","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1002\/psp4.13313","volume":"14","author":"D Valderrama","year":"2025","unstructured":"Valderrama D, Teplytska O, Koltermann LM, Trunz E, Schmulenson E, Fritsch A, et al. Comparing scientific machine learning with population pharmacokinetic and classical machine learning approaches for prediction of drug concentrations. CPT Pharmacometrics Syst Pharmacol United States. 2025;14:759\u201369. https:\/\/doi.org\/10.1002\/psp4.13313.","journal-title":"CPT Pharmacometrics Syst Pharmacol United States"},{"key":"8063_CR19","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1002\/psp4.12870","volume":"11","author":"J Gill","year":"2022","unstructured":"Gill J, Moullet M, Martinsson A, Miljkovi\u0107 F, Williamson B, Arends RH, et al. Comparing the applications of machine learning, PBPK, and population pharmacokinetic models in pharmacokinetic drug-drug interaction prediction. CPT Pharmacometrics Syst Pharmacol United States. 2022;11:1560\u201368. https:\/\/doi.org\/10.1002\/psp4.12870.","journal-title":"CPT Pharmacometrics Syst Pharmacol United States"},{"key":"8063_CR20","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.jad.2023.11.047","volume":"347","author":"C-W Hsu","year":"2024","unstructured":"Hsu C-W, Lai EC-C, Chen Y-CB, Kao H-Y. Valproic acid monitoring: serum prediction using a machine learning framework from multicenter real-world data. J Affect Disord Netherlands. 2024;347:85\u201391. https:\/\/doi.org\/10.1016\/j.jad.2023.11.047.","journal-title":"J Affect Disord Netherlands"},{"key":"8063_CR21","doi-asserted-by":"publisher","unstructured":"Zhu X, Zhang M, Wen Y, Shang D. Machine learning advances the integration of covariates in population pharmacokinetic models: valproic acid as an example. Front Pharmacol Switzerland. 2022;13:994665. https:\/\/doi.org\/10.3389\/fphar.2022.994665.","DOI":"10.3389\/fphar.2022.994665"},{"key":"8063_CR22","doi-asserted-by":"publisher","first-page":"1521932","DOI":"10.3389\/fphar.2024.1521932","volume":"15","author":"Y-W Chen","year":"2024","unstructured":"Chen Y-W, Lin X-K, Chen S, Zhang Y-L, Wu W, Huang C, et al. Monitoring of the trough concentration of valproic acid in pediatric epilepsy patients: a machine learning-based ensemble model. Front Pharmacol Switzerland. 2024;15:1521932. https:\/\/doi.org\/10.3389\/fphar.2024.1521932.","journal-title":"Front Pharmacol Switzerland"},{"key":"8063_CR23","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.3171\/2022.8.JNS22744","volume":"138","author":"IA Tewarie","year":"2023","unstructured":"Tewarie IA, Senko AW, Jessurun CAC, Zhang AT, Hulsbergen AFC, Rendon L, et al. Predicting leptomeningeal disease spread after resection of brain metastases using machine learning. J Neurosurg United States. 2023;138:1561\u201369. https:\/\/doi.org\/10.3171\/2022.8.JNS22744.","journal-title":"J Neurosurg United States"},{"key":"8063_CR24","doi-asserted-by":"publisher","first-page":"106424","DOI":"10.1016\/j.cmpb.2021.106424","volume":"211","author":"W Seo","year":"2021","unstructured":"Seo W, Park S-W, Kim N, Jin S-M, Park S-M. A personalized blood glucose level prediction model with a fine-tuning strategy: a proof-of-concept study. Comput Methods Programs Biomed Ireland. 2021;211:106424. https:\/\/doi.org\/10.1016\/j.cmpb.2021.106424.","journal-title":"Comput Methods Programs Biomed Ireland"},{"key":"8063_CR25","doi-asserted-by":"publisher","unstructured":"Li Y, Sun H, Yan W, Zhang X. Multi-output parameter-insensitive kernel twin SVR model. Neural Netw United States. 2020;121:276\u201393. https:\/\/doi.org\/10.1016\/j.neunet.2019.09.022.","DOI":"10.1016\/j.neunet.2019.09.022"},{"key":"8063_CR26","doi-asserted-by":"publisher","unstructured":"Bilbao-Meseguer I, Barrasa H, As\u00edn-Prieto E, Alarcia-Lacalle A, Rodr\u00edguez-Gasc\u00f3n A, Maynar J, et al. Population pharmacokinetics of levetiracetam and dosing evaluation in critically Ill patients with normal or augmented renal function. Pharm. Switz. 2021;13(10):1690. https:\/\/doi.org\/10.3390\/pharmaceutics13101690","DOI":"10.3390\/pharmaceutics13101690"},{"key":"8063_CR27","doi-asserted-by":"publisher","first-page":"333","DOI":"10.2165\/00003088-200847050-00004","volume":"47","author":"N Toublanc","year":"2008","unstructured":"Toublanc N, Sargentini-Maier ML, Lacroix B, Jacqmin P, Stockis A. Retrospective population pharmacokinetic analysis of levetiracetam in children and adolescents with epilepsy: dosing recommendations. Clin Pharmacokinet Switzerland. 2008;47:333\u201341. https:\/\/doi.org\/10.2165\/00003088-200847050-00004.","journal-title":"Clin Pharmacokinet Switzerland"},{"key":"8063_CR28","doi-asserted-by":"publisher","unstructured":"Teixeira-da-Silva P, P\u00e9rez-Blanco JS, Santos-Buelga D, Otero MJ, Garc\u00eda MJ. Population pharmacokinetics of valproic acid in pediatric and adult caucasian patients. Pharm. Switz. 2022;14(4):811. https:\/\/doi.org\/10.3390\/pharmaceutics14040811","DOI":"10.3390\/pharmaceutics14040811"},{"key":"8063_CR29","doi-asserted-by":"publisher","unstructured":"Li Z-R, Wang C-Y, Zhu X, Jiao Z. Population pharmacokinetics of levetiracetam: a systematic review. Clin Pharmacokinet Switzerland. 2021;60:305\u201318. https:\/\/doi.org\/10.1007\/s40262-020-00963-2.","DOI":"10.1007\/s40262-020-00963-2"},{"key":"8063_CR30","doi-asserted-by":"publisher","first-page":"503","DOI":"10.2165\/00003088-200746060-00004","volume":"46","author":"E Pigeolet","year":"2007","unstructured":"Pigeolet E, Jacqmin P, Sargentini-Maier M-L, Stockis A. Population pharmacokinetics of levetiracetam in Japanese and Western adults. Clin Pharmacokinet Switzerland. 2007;46:503\u201312. https:\/\/doi.org\/10.2165\/00003088-200746060-00004.","journal-title":"Clin Pharmacokinet Switzerland"},{"key":"8063_CR31","doi-asserted-by":"publisher","unstructured":"Perucca E, Gidal BE, Balt\u00e8s E. Effects of antiepileptic comedication on levetiracetam pharmacokinetics: a pooled analysis of data from randomized adjunctive therapy trials. Epilepsy Res. Vol. 53. Netherlands; 2003. p. 47\u201356. https:\/\/doi.org\/10.1016\/s0920-1211(02)00250-4.","DOI":"10.1016\/s0920-1211(02)00250-4"},{"key":"8063_CR32","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1186\/s13054-025-05396-6","volume":"29","author":"MC Paulus","year":"2025","unstructured":"Paulus MC, Melchers M, van Es A, Kouw IWK, van Zanten ARH. The urea-to-creatinine ratio as an emerging biomarker in critical care: a scoping review and meta-analysis. Crit Care England. 2025;29:175. https:\/\/doi.org\/10.1186\/s13054-025-05396-6.","journal-title":"Crit Care England"},{"key":"8063_CR33","doi-asserted-by":"publisher","unstructured":"Glavind E, Aagaard NK, Gr\u00f8nb\u00e6k H, M\u00f8ller HJ, Orntoft NW, Vilstrup H, et al. Alcoholic hepatitis markedly decreases the capacity for urea synthesis. PLoS One United States. 2016;11:e0158388. https:\/\/doi.org\/10.1371\/journal.pone.0158388.","DOI":"10.1371\/journal.pone.0158388"},{"key":"8063_CR34","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1007\/s12028-018-0627-4","volume":"30","author":"A Drisaldi","year":"2019","unstructured":"Drisaldi A, Weeda E, Neyens R, Orvin N, Bonilha L, Campbell Z, et al. Accuracy of valproic acid concentration correction based on Serum albumin. Neurocrit Care United States. 2019;30:301\u201306. https:\/\/doi.org\/10.1007\/s12028-018-0627-4.","journal-title":"Neurocrit Care United States"},{"key":"8063_CR35","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/1824-7288-37-21","volume":"37","author":"M Mazaheri","year":"2011","unstructured":"Mazaheri M, Samaie A, Semnani V. Renal tubular dysfunction measured by N-acetyl-beta glucosaminidase\/Creatinine activity index in children receiving antiepileptic drugs: a randomized controlled trial. Ital J Pediatr England. 2011;37:21. https:\/\/doi.org\/10.1186\/1824-7288-37-21.","journal-title":"Ital J Pediatr England"},{"key":"8063_CR36","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1007\/s00467-013-2512-x","volume":"29","author":"MJ Knights","year":"2014","unstructured":"Knights MJ, Finlay E. The effects of sodium valproate on the renal function of children with epilepsy. Pediatr Nephrol Germany. 2014;29:1131\u201338. https:\/\/doi.org\/10.1007\/s00467-013-2512-x.","journal-title":"Pediatr Nephrol Germany"},{"key":"8063_CR37","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1007\/s00134-019-05760-5","volume":"45","author":"RW Haines","year":"2019","unstructured":"Haines RW, Zolfaghari P, Wan Y, Pearse RM, Puthucheary Z, Prowle JR. Elevated urea-to-creatinine ratio provides a biochemical signature of muscle catabolism and persistent critical illness after major trauma. Intensive Care Med United States. 2019;45:1718\u201331. https:\/\/doi.org\/10.1007\/s00134-019-05760-5.","journal-title":"Intensive Care Med United States"},{"key":"8063_CR38","doi-asserted-by":"publisher","unstructured":"Yanai H, Adachi H, Hakoshima M, Katsuyama H. Molecular biological and clinical understanding of the pathophysiology and treatments of hyperuricemia and its association with metabolic syndrome, cardiovascular diseases and chronic kidney disease. Int J Mol Sci Switzerland. 2021;22(17):9221 . https:\/\/doi.org\/10.3390\/ijms22179221","DOI":"10.3390\/ijms22179221"},{"key":"8063_CR39","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1111\/epi.16472","volume":"61","author":"SA Choi","year":"2020","unstructured":"Choi SA, Kim H, Kim S, Yoo S, Yi S, Jeon Y, et al. Analysis of antiseizure drug-related adverse reactions from the electronic health record using the common data model. Epilepsia United States. 2020;61:610\u201316. https:\/\/doi.org\/10.1111\/epi.16472.","journal-title":"Epilepsia United States"},{"key":"8063_CR40","doi-asserted-by":"publisher","unstructured":"Olaizola I, Brodde MF, Kehrel BE, Evers S. The impact of levetiracetam and valproate on platelet functions-A Double-blind, placebo-controlled crossover study. J Clin Med Switzerland. 2023;12(3):933. https:\/\/doi.org\/10.3390\/jcm12030933","DOI":"10.3390\/jcm12030933"},{"key":"8063_CR41","doi-asserted-by":"publisher","first-page":"707","DOI":"10.2165\/00003088-200443110-00002","volume":"43","author":"PN Patsalos","year":"2004","unstructured":"Patsalos PN. Clinical pharmacokinetics of levetiracetam. Clin Pharmacokinet Switzerland. 2004;43:707\u201324. https:\/\/doi.org\/10.2165\/00003088-200443110-00002.","journal-title":"Clin Pharmacokinet Switzerland"},{"key":"8063_CR42","doi-asserted-by":"publisher","unstructured":"Freitas-Lima P, Alexandre VJ, Pereira LRL, Feletti F, Perucca E, Sakamoto AC. Influence of enzyme inducing antiepileptic drugs on the pharmacokinetics of levetiracetam in patients with epilepsy. Epilepsy ResNetherlands.2011;94(1-2)117\u201320. https:\/\/doi.org\/10.1016\/j.eplepsyres.2011.01.007","DOI":"10.1016\/j.eplepsyres.2011.01.007"},{"key":"8063_CR43","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1111\/bcpt.13203","volume":"125","author":"B Koristkova","year":"2019","unstructured":"Koristkova B, Grundmann M, Brozmanova H, Kacirova I. Lamotrigine drug interactions in combination therapy and the influence of therapeutic drug monitoring on clinical outcomes in paediatric patients. Basic Clin Pharmacol Toxicol England. 2019;125:26\u201333. https:\/\/doi.org\/10.1111\/bcpt.13203.","journal-title":"Basic Clin Pharmacol Toxicol England"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-026-08063-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-08063-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-08063-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T14:15:02Z","timestamp":1778163302000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12967-026-08063-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,31]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8063"],"URL":"https:\/\/doi.org\/10.1186\/s12967-026-08063-8","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,31]]},"assertion":[{"value":"25 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declared no competing interests for this work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"645"}}